Tech Company Financing Transactions
Aurion Biotech Funding Round
Aurion Biotech secured a $120 million funding round on 4/12/2022. Investors included Deerfield Management Company, Falcon Vision and Flying L Partners.
Transaction Overview
Company Name
Announced On
4/12/2022
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Funds will be disbursed to the Company based on the achievement of key clinical and operational milestones.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Seattle, WA Undisclosed
USA
Seattle, WA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Every day, we live our values of grit, stewardship and transformation -- all with the purpose of improving our patients' quality of life. Our first drug candidate was acquired from Professor Shigeru Kinoshita -- one of the world's leading ophthalmologists and ophthalmic research scientists -- and his distinguished colleagues at Kyoto Prefecture University of Medicine in Japan.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Greg Kunst
Chief Financial Officer
David Rostov
Chief Medical Officer
Eris Jordan
Chief Scientific Officer
Arnaud Lacoste
VP - Manufacturing
Tim Largen
VP - Marketing
Judith McGarry
Browse more venture capital transactions:
Prev: 4/12/2022: Real Therapy venture capital transaction
Next: 4/12/2022: Omni Analytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs